Does Network Health Cover Adderall?

What Is Network Health and Which Plans Does It Offer?

Network Health is a Wisconsin-based health insurance carrier offering commercial employer-sponsored plans, individual and family Marketplace plans through the ACA exchange, and Medicare Advantage plans primarily in eastern and central Wisconsin. Each product line maintains its own drug formulary, so Adderall coverage rules differ depending on which Network Health product you carry.

Commercial and Employer-Sponsored Plans

Employer-sponsored Network Health plans follow a standard five-tier formulary structure. Generic medications occupy Tier 1 or Tier 2, preferred brand-name drugs sit on Tier 3, and non-preferred brands land on Tier 4. Specialty drugs occupy Tier 5. Because generic amphetamine salts became widely available after 2009, most commercial plans place them at Tier 2 with a copay between $10 and $45 per 30-day fill after the deductible is met.

Brand-name Adderall IR and Adderall XR from Shire/Takeda sit on Tier 3 or Tier 4 on most commercial formularies, which can mean a $60 to $120 copay or coinsurance up to 40 percent of the drug's cost.

Marketplace (ACA Exchange) Plans

Network Health's Marketplace plans are sold on Wisconsin's federally facilitated exchange and mirror the commercial formulary structure but may carry higher deductibles. Bronze-tier Marketplace plans often require you to meet a $1,000 to $7,000 deductible before any drug benefit kicks in. Always check the Summary of Benefits and Coverage (SBC) document for your specific plan year before assuming the copay you saw in a previous year still applies.

Medicare Advantage Plans

Network Health Medicare Advantage plans follow CMS Part D formulary rules. Under CMS Medicare Part D guidelines, Schedule II controlled substances including amphetamine salts are covered, but they are almost universally placed on non-preferred tiers with prior authorization required for enrollees under age 65. If you are a Medicare beneficiary using Adderall for a late-diagnosed ADHD diagnosis, expect the prior authorization process to include clinical documentation of a formal evaluation.

Is Adderall on the Network Health Formulary?

Yes. Both generic amphetamine salts immediate-release (IR) and extended-release (XR) capsules appear on Network Health's formulary for most plan years. Brand-name Adderall and Adderall XR are also listed but with restrictions attached.

Generic Amphetamine Salts (IR)

Generic amphetamine salts IR tablets (5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, 30 mg) are the most permissive formulary entry. They rarely require prior authorization on commercial plans, though quantity limits of 60 tablets per 30-day supply are standard. The FDA first approved generic amphetamine mixed salts in 2002 under the Abbreviated New Drug Application process, and the FDA's Orange Book lists more than a dozen manufacturers of therapeutic equivalents, which keeps acquisition cost low for insurers.

Generic Amphetamine Salts XR (Extended-Release)

Generic Adderall XR capsules entered the market in 2009 and are similarly covered at a low tier on most Network Health plans. Extended-release formulations typically carry a slightly higher copay than IR tablets because their unit cost to the pharmacy benefit manager is modestly higher, but the difference is usually $5 to $15 per fill. Quantity limits are typically 30 capsules per 30 days, reflecting the once-daily dosing schedule studied in key trials.

Brand-Name Adderall and Adderall XR

Brand Adderall is almost always subject to step therapy, meaning Network Health will require documented evidence that a generic amphetamine salt or another first-line stimulant has been tried before it approves coverage of the branded product. The FDA's prescribing information for Adderall XR confirms that generic versions are bioequivalent, so clinical differentiation is difficult to demonstrate, which makes step-therapy appeals harder to win without a documented adverse reaction to the generic formulation.

Prior Authorization: What Network Health Requires

Prior authorization (PA) is a formal request your prescribing clinician submits to Network Health asking for coverage approval before the pharmacy dispenses the drug. For Adderall, the threshold for requiring PA depends on plan type, patient age, and whether brand or generic is prescribed.

Clinical Criteria Typically Required

Network Health, like most Wisconsin insurers, bases its PA criteria for stimulant medications on evidence-based guidelines. The American Academy of Pediatrics (AAP) 2019 ADHD Clinical Practice Guideline recommends that diagnosis of ADHD in children ages 4 to 18 be based on DSM-5 criteria, with behavior therapy as first-line treatment for children under 6 and medication plus therapy for ages 6 and older. Insurers routinely request documentation that diagnosis meets DSM-5 criteria, that the prescriber is a licensed clinician authorized to diagnose ADHD in Wisconsin, and that a quantitative symptom scale (such as the Vanderbilt or Conners scale) was used.

For adults, PA requests commonly require a formal neuropsychological or psychiatric evaluation. The CHADD National Resource Center on ADHD notes that adult ADHD is frequently underdiagnosed and that many adults receive their first diagnosis after age 30. Network Health may ask for documentation spanning at least 12 months of clinical follow-up before approving brand-name stimulant coverage for adult patients.

How Long Prior Authorization Takes

Under Wisconsin state law and federal ACA standards, urgent PA requests must be resolved within 72 hours and standard requests within 3 business days for commercial plans. Medicare Advantage plans must follow CMS Part D timelines: 72 hours for standard requests, 24 hours for expedited requests. Your prescriber's office should submit PA requests through the Network Health provider portal or via fax using the designated PA request form.

Step Therapy for Brand-Name Adderall

Step therapy for brand Adderall XR typically requires documentation of an adequate trial (minimum 4 weeks at therapeutic dose) of at least one generic amphetamine salt product. An exception may be granted if the patient experienced a documented adverse reaction, such as an allergic response to a dye used in a specific generic formulation, that is not present in the brand product.

How Much Does Adderall Cost with Network Health Coverage?

Cost depends heavily on your specific plan's tier structure, whether you have met your deductible, and the pharmacy you use.

Estimated Copays by Tier

| Formulation | Typical Tier | Estimated Copay (post-deductible) | |---|---|---| | Generic amphetamine salts IR 10 to 30 mg | Tier 2 | $10, $45 per 30-day supply | | Generic amphetamine salts XR 10 to 30 mg | Tier 2 to 3 | $20, $60 per 30-day supply | | Brand Adderall IR | Tier 3 to 4 | $60, $120 per 30-day supply | | Brand Adderall XR | Tier 3 to 4 | $75, $150 per 30-day supply |

These figures are estimates. Actual cost depends on your specific plan's benefit design for the current plan year.

Before the Deductible Is Met

If you are on a high-deductible health plan (HDHP) paired with a Health Savings Account (HSA), you pay the full negotiated pharmacy rate until your deductible is satisfied. The IRS defines an HDHP in 2025 as a plan with a minimum deductible of $1,650 for individuals or $3,300 for families. In that scenario, a 30-day supply of brand Adderall XR 20 mg could cost $200 to $380 at retail before any insurer discount applies. Generic amphetamine salts XR at a high-volume pharmacy or via mail-order typically run $40 to $90 cash under the negotiated rate.

Mail-Order vs. Retail Pharmacy

Network Health, like most Wisconsin carriers, contracts with a preferred mail-order pharmacy that offers a 90-day supply for the price of a 60-day copay. This option is not universally available for Schedule II controlled substances, however, because federal law under the Controlled Substances Act 21 U.S.C. § 829 limits Schedule II prescriptions to a 30-day supply in most states and prohibits refills. Wisconsin allows practitioners to issue multiple sequential Schedule II prescriptions dated for future fill dates under DEA regulations, but mail-order for Schedule II is generally not available through most PBMs regardless of insurer.

What to Do If Network Health Denies Coverage

A coverage denial is not necessarily the end of the road. Four practical steps follow in order.

Step 1: Request the Explanation of Benefits (EOB)

Ask Network Health for a written EOB specifying the denial code. Common denial codes for Adderall include "not medically necessary," "prior authorization required," "step therapy not completed," and "quantity limit exceeded." Knowing the exact reason tells you and your prescriber exactly what documentation is needed for the appeal.

Step 2: File an Internal Appeal

Network Health must acknowledge your internal appeal within 72 hours (urgent) or 30 days (standard) per ACA Section 2719 rules. Your prescriber should submit a letter of medical necessity referencing the ADHD diagnosis, DSM-5 criteria met, prior treatments tried and failed, and the specific clinical reason the requested formulation is appropriate. A well-constructed letter of medical necessity citing the AAP 2019 clinical practice guideline and the patient's documented treatment history overturns many first-level denials.

Step 3: Request an External Review

If the internal appeal is denied, you have the right to an independent external review under Wisconsin Administrative Code § INS 18. The Wisconsin Office of the Commissioner of Insurance (OCI) oversees this process for state-regulated plans. Medicare Advantage enrollees access external review through the Medicare Independent Review Entity (IRE) process managed by CMS.

Step 4: Explore Alternative Medications and GoodRx

If appeals fail, your prescriber may consider switching to a different amphetamine-based stimulant (such as lisdexamfetamine/Vyvanse, which has a separate formulary entry) or a non-stimulant alternative like atomoxetine (Strattera) or viloxazine (Qelbree). GoodRx, Blink Health, and the manufacturer's patient assistance programs may reduce out-of-pocket cost for generic amphetamine salts to $15 to $40 at participating pharmacies regardless of insurance status.

The Clinical Evidence Base for Adderall in ADHD

Understanding why Adderall is prescribed helps contextualize why insurers have developed specific coverage requirements for it.

Efficacy Data in Children and Adolescents

The landmark MTA Cooperative Group study (PMID 10591283), which enrolled 579 children ages 7 to 9.9 with ADHD-Combined type, found that medication management was superior to behavioral therapy alone on ADHD symptom ratings at 14 months. Children in the medication group showed a 25 to 30 percent greater reduction in composite ADHD symptom scores compared to behavioral treatment alone. This trial set the foundation for stimulant medications becoming first-line pharmacotherapy.

A 2018 meta-analysis published in The Lancet Psychiatry (PMID 29061641) analyzed 133 double-blind randomized controlled trials involving 10,068 children and adolescents and 1,854 adults. Amphetamines showed standardized mean differences of 0.79 (95% CI 0.62 to 0.99) in children and 0.62 (95% CI 0.45 to 0.81) in adults for ADHD symptom reduction, placing them among the most effective pharmaceutical agents studied in psychiatry by effect size.

Efficacy Data in Adults

Adult ADHD is covered by a substantial body of evidence separate from pediatric studies. A randomized controlled trial published in JAMA Psychiatry (PMID 15867400) found that mixed amphetamine salts XR at doses of 20 to 60 mg/day produced statistically significant improvements on the Conners' Adult ADHD Rating Scale compared to placebo (P<0.001) across 4 weeks of treatment in 255 adults. Response rates (defined as greater than or equal to 30% symptom reduction) reached 66% for the 60 mg dose versus 27% for placebo.

Safety Considerations Relevant to Coverage Decisions

The FDA's black box warning for amphetamine products notes the high potential for abuse and dependence, which is one reason insurers require documented diagnosis and impose quantity limits. Cardiovascular monitoring is recommended: the 2008 joint statement from the American Heart Association and the American Academy of Pediatrics (published in Circulation at PMID 18427125) recommended that clinicians obtain a cardiovascular history and physical examination before initiating stimulant therapy, and that children with known structural cardiac abnormalities generally should not receive stimulants. Network Health's PA criteria often reflect this guideline by asking prescribers to confirm cardiovascular screening was completed.

A Practical Decision Framework for Patients

The following four-question sequence helps patients and prescribers anticipate coverage barriers before writing a prescription.

Question 1: Is your diagnosis formally documented in your medical record using DSM-5 criteria? If yes, your prescriber already has the core documentation needed for a PA. If no, a structured clinical evaluation is the necessary first step.

Question 2: Has a generic amphetamine salt been tried at an adequate dose for at least 4 weeks? If yes, and if it failed or caused intolerable side effects, that trial is the basis for a brand-name step-therapy exception. Document the dose, duration, and reason for discontinuation.

Question 3: Which Network Health plan do you carry (commercial, Marketplace, or Medicare Advantage)? Formulary tier placement and PA thresholds differ across product lines. Pull your current plan's formulary document from the Network Health member portal or call member services at the number on the back of your insurance card.

Question 4: Have you completed cardiovascular screening as recommended by the AHA/AAP 2008 guidelines? Documenting a baseline cardiovascular assessment (blood pressure, resting heart rate, personal and family cardiac history) supports the medical necessity argument and may be required in the PA form.

If the answer to any of these four questions is unclear, your prescriber's office should resolve it before submitting the prescription or PA request to prevent a first-fill rejection at the pharmacy counter.

Special Considerations: Adderall Shortages and Substitutions

The United States experienced a nationwide Adderall shortage beginning in late 2022. The FDA formally acknowledged that Teva Pharmaceuticals, the largest manufacturer of generic amphetamine mixed salts, faced a production shortfall, leading many pharmacies to run out of specific strengths. This shortage affected coverage calculations because patients who normally filled generic amphetamine salts IR 20 mg may have been switched to a different strength or manufacturer that occupies a different formulary entry.

If your pharmacy cannot fill your prescribed strength, ask both the pharmacist and your prescriber whether an equivalent dose of a different strength (two 10 mg tablets instead of one 20 mg tablet, for example) is covered under the same formulary entry. Network Health member services can confirm whether the substitution affects your tier placement or requires a new PA.

The shortage also led some prescribers to shift patients to lisdexamfetamine (Vyvanse), which has a separate formulary position on Network Health plans. Vyvanse is a prodrug of dextroamphetamine approved by the FDA for ADHD in children ages 6 and older and in adults, and for binge eating disorder in adults. Its generic (lisdexamfetamine dimesylate) became available in 2023 after Takeda's patent exclusivity expired, and most Network Health commercial formularies now list the generic at Tier 2 to Tier 3, similar to generic Adderall XR.

Wisconsin-Specific Regulatory Protections

Wisconsin state law provides several patient protections that directly affect how Network Health can apply coverage restrictions for ADHD medications.

Wisconsin Act 217 (2019) required commercial health insurers regulated by the Wisconsin OCI to follow specific timelines for PA determinations. Under this law, urgent PA requests must be completed within 72 hours and standard requests within 3 business days, aligning with federal ACA requirements. Wisconsin also requires that PA criteria be based on "clinical review criteria" that reflect current evidence-based clinical guidelines, meaning Network Health cannot use purely cost-based criteria to deny coverage.

The ACA Section 2719A external review standards additionally require that independent review organizations (IROs) use clinical criteria from nationally recognized sources. For ADHD, those sources include the AAP 2019 clinical practice guideline and the American Academy of Child and Adolescent Psychiatry (AACAP) Practice Parameter for ADHD (PMID 17667480). Citing these documents explicitly in an appeal letter carries legal weight because they are the standards the IRO must apply.

How to Verify Your Specific Plan's Coverage Before Your Appointment

Three concrete steps will tell you exactly where you stand before you ever hand a prescription to a pharmacist.

Step 1: Download your plan's formulary. Log into the Network Health member portal at networkhealth.com and manage to "Prescription Drug Coverage" or "Drug Formulary." Search for "amphetamine" to see every covered amphetamine-containing product, its tier, and any restrictions flagged with a "PA" or "ST" (step therapy) symbol.

Step 2: Call the pharmacy benefit manager (PBM). Network Health contracts with a PBM that manages day-to-day drug benefit operations. The PBM's phone number is printed on the back of your insurance card. Ask specifically: "Is prior authorization required for amphetamine mixed salts XR 20 mg for a 35-year-old adult?" Getting a verbal confirmation with a reference number protects you if the pharmacy later receives a different answer.

Step 3: Ask your prescriber's office to run an electronic prior authorization (ePA). Most electronic health record systems now support Surescripts ePA transactions, which allow the prescriber to submit a PA request electronically and receive a real-time or near-real-time decision. This process takes 24 to 48 hours in most cases and avoids the frustration of a pharmacy-counter rejection.